Sponsored by
Unfortunately, this trial failed. It may have failed because the vaccine was started too late - at the time of recurrence. It makes a lot more sense to try it for newly diagnosed healthier patients. Adding in a checkpoint inhibitor should also help. Lastly, with other vaccines, the early readings of the trial did not look good, but as time goes on, there was a small group of patients who do well for a much longer time than expected.